10x Science Raises $4.8 Million to Speed Up AI-Driven Drug Discovery

10x Science has raised $4.8 million to accelerate protein characterization, tackling the bottleneck in drug discovery.

10x Science Raises $4.8 Million to Speed Up AI-Driven Drug Discovery
10x Science logo, a startup focused on AI for protein characterization.

Drug discovery is undergoing a revolution thanks to artificial intelligence (AI), which has significantly increased the number of potential therapeutic candidates. However, this progress has created a new bottleneck: the need to accurately characterize these proteins to determine their efficacy and safety. 10x Science, a startup founded in December 2025, recently raised $4.8 million in a seed round led by Initialized Capital and backed by Y Combinator, Civilization Ventures and Founder Factor, to tackle this critical challenge.

The Bottleneck in Drug Discovery

Although AI is accelerating the early phase of drug discovery, protein characterization remains a significant obstacle. Advanced techniques such as mass spectrometry, which analyzes the atomic structure of molecules, generate complex data that takes time and specialized expertise to interpret. This slows the entire drug development process and prevents promising candidates from moving quickly from research into clinical practice.

10x Science's Proposed Solution

10x Science offers an AI-native platform designed to automate and accelerate protein characterization. By combining deterministic algorithms based on chemistry and biology with AI agents able to interpret the data, the platform aims to significantly reduce the time needed to evaluate therapeutic candidates. This approach lets drug developers focus on promising molecules, improving the efficiency and effectiveness of the development process.

Implications for the Pharmaceutical Industry

Integrating AI into protein characterization is a key step in overcoming current challenges in drug discovery. With rising funding and the adoption of advanced technologies, companies such as 10x Science are helping to transform pharmaceutical research. This not only speeds up the development of new treatments but also opens opportunities to address diseases previously considered incurable, improving patients' quality of life worldwide.

Conclusion

  • Accelerating drug discovery: AI is shortening drug development timelines, leading to faster treatments for patients.
  • Automating protein characterization: Platforms such as 10x Science's simplify protein analysis, improving the efficiency of the process.
  • Opportunities for incurable diseases: Advanced technologies offer new hope for treating conditions previously without a cure.
  • Strategic collaborations: Investment and partnerships between startups and academic institutions are accelerating innovation in the sector.
  • Global impact: AI adoption in pharmaceutical research has the potential to improve global health through more effective and timely treatments.